July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Evaluation of congenital color vision deficiency using the Rabin cone contrast test
Author Affiliations & Notes
  • Maki Iwasa
    Department of Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan
  • Sanae Muraki
    Department of Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan
    Muraki eye clinic, Japan
  • Shinichi Yamade
    Department of Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan
  • Masahito Ohji
    Department of Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan
  • Footnotes
    Commercial Relationships   Maki Iwasa, None; Sanae Muraki, None; Shinichi Yamade, None; Masahito Ohji, Alcon Pharmaceuticals (F), Alcon Pharmaceuticals (R), Allergan Japan (R), Bayer Yakuhin,Ltd. (C), CHUO SANGIO CO. (R), HOYA Corporation (F), HOYA Corporation (C), Kowa (R), Kowa (C), Novartis Pharma (F), Novartis Pharma (R), Novartis Pharma (C), Otsuka Pharmaceutical Co., Ltd. (F), Otsuka Pharmaceutical Co., Ltd. (R), Pfizer Inc. (F), Pfizer Inc. (R), R E Medical,INC. (R), Santen Pharmaceutical Co., Ltd. (F), Santen Pharmaceutical Co., Ltd. (R), Santen Pharmaceutical Co., Ltd. (C), SENJU PHARMACEUTICAL CO., LTD. (F), SENJU PHARMACEUTICAL CO., LTD. (R), Topcon (R), Zeiss (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1308. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maki Iwasa, Sanae Muraki, Shinichi Yamade, Masahito Ohji; Evaluation of congenital color vision deficiency using the Rabin cone contrast test. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1308.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the clinical validity of the Rabin cone contrast test (RCCT; Innova Systems, Inc.) in patients with congenital color vision deficiency (CVD).

Methods : L, M and S-CCT scores (range,0-100) in the RCCT and the RCCT sensitivity and specificity were evaluated in 161 men with congenital CVD ( 22 with protanopia, 23 with protanomaly, 61 with deuteranopia and 55 with deuteranomaly; mean age±SD,14.9±5.5 years) and 10 controls ( mean age±SD,11.0±1.8 years). They were diagnosed by examination with an anomaloscope (Model1, Schmidt and Haensch, Berlin, Germany). All participants had Snellen best corrected visual acuity (BCVA) of 20/20 or better Snellen best corrected visual acuity (BCVA).

Results : Mean L, M and S-CCT scores were 24.5±13.5, 93.0±8.9 and 99.8±1.0 in protanope; 56.3±22.9, 95.4±4.6 and 100±0 in protanomal; 95.0±11.5, 55.6±17.9 and 98.4±4.1 in deuteranope; 94.7±7.5, 59.5±16.6 and 99.3±2.2 in deuteranomaly; 97.0±4.0, 97.5±3.4 and 99.0±2.0 in controls. Score of 75 or less is defined as abnormal based on Rabin Cone Contrast Test recommendation, when we use the normal score on the CCT( 75≧), the sensitivity was 88.8% and the specificity was 100% for diagnosing the CVD types using the RCCT. To compare the standard Ishihara test with the RCCT, 95.6% of protan and 97.4% of deutan were matched the type of CVD in the RCCT, 44.4% of protan and 97.4% of deutan were matched the type of CVD in the Ishihara test. The standard Ishihara test has 98.8% sensitivity and 100% specificity for diagnosing the CVD. Among 45 patients of protan, 43 patients were determined as P type in the RCCT, while 18 protan were determined as P type in the Ishihara test. Among 116 patients of deutan, 113 deutan were determined as D type both in the RCCT and the Ishihara test.

Conclusions : The RCCT is useful for CVD screening and typing. Compared with the Ishihara test, the RCCT is particularly useful the detection of protan.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×